GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stimcell Energetics Inc (OTCPK:CMXCD) » Definitions » Debt-to-Revenue

CMXCD (Stimcell Energetics) Debt-to-Revenue : N/A (As of Aug. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Stimcell Energetics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Stimcell Energetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $0.32 Mil. Stimcell Energetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $0.00 Mil. Stimcell Energetics's annualized Revenue for the quarter that ended in Aug. 2024 was $0.00 Mil.


Stimcell Energetics Debt-to-Revenue Historical Data

The historical data trend for Stimcell Energetics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stimcell Energetics Debt-to-Revenue Chart

Stimcell Energetics Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 43.14 102.83 333.67 N/A

Stimcell Energetics Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Stimcell Energetics's Debt-to-Revenue

For the Medical Devices subindustry, Stimcell Energetics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stimcell Energetics's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Stimcell Energetics's Debt-to-Revenue falls into.



Stimcell Energetics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Stimcell Energetics's Debt-to-Revenue for the fiscal year that ended in May. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.313 + 0) / N/A
=N/A

Stimcell Energetics's annualized Debt-to-Revenue for the quarter that ended in Aug. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Aug. 2024) Revenue data.


Stimcell Energetics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stimcell Energetics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Stimcell Energetics Business Description

Traded in Other Exchanges
N/A
Address
1130 Pender Street, West, Suite 820, Vancouver, BC, CAN, V6E 4A4
Cell MedX Corp is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health, anti-aging, pain relief, wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, insulin resistance, high blood pressure, neuropathy and kidney function. It is also engaged in development and manufacturing of therapeutic devices which harnesses the power of microcurrents and their effects on the human body.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Stimcell Energetics Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson 11-11-2016